Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Europe's drug committee gives sintilimab the green light for nonsquamous NSCLC. The EMA's CHMP has issued a positive opinion for sintilimab (Zybrivo) combined with chemotherapy as a first-line treatment for adults with nonsquamous non–small cell lung cancer. The recommendation is backed by phase 3 ORIENT-11 trial data showing significant improvements in survival outcomes. A final European Commission decision is expected in the coming months.
Europe edges closer to approving sintilimab for first-line lung cancer treatment
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorization for sintilimab (Zybrivo), a PD-1 inhibitor, in combination with pemetrexed and platinum-based chemotherapy. The indication covers first-line treatment of adults with locally advanced or metastatic nonsquamous non–small cell lung cancer (NSCLC). The European Commission is expected to issue a final approval decision in the coming months.
The recommendation is grounded in data from the randomized, double-blind phase 3 ORIENT-11 trial, which enrolled 397 patients with nonsquamous NSCLC lacking EGFR or ALK aberrations. The safety profile was consistent with known PD-1 inhibitor and chemotherapy profiles, with no new safety signals identified.
By the Numbers
Why it matters: While the FDA rejected sintilimab in 2022 — citing concerns that ORIENT-11 data wasn't representative of the U.S. population — the CHMP's positive opinion signals a meaningful regulatory win for Innovent Biologics in Europe, potentially expanding treatment options for nonsquamous NSCLC patients there.